AKBA Akebia Therapeutics Inc
Price (delayed)
$1.91
Market cap
$451.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$441.57M
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is
Highlights
The company's quick ratio rose by 30% YoY and by 6% QoQ
AKBA's debt is down by 3.2% year-on-year and by 2.4% since the previous quarter
The equity has dropped by 61% year-on-year but it is up by 2.4% since the previous quarter
AKBA's net income has plunged by 51% from the previous quarter and by 34% YoY
Akebia Therapeutics's EPS has decreased by 43% from the previous quarter and by 18% YoY
Key stats
What are the main financial stats of AKBA
Market
Valuations
Earnings
Shares outstanding
236.23M
Market cap
$451.2M
Enterprise value
$441.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.76
Revenue
$160.18M
Gross profit
$97M
Operating income
-$47.25M
Net income
-$69.41M
EBIT
-$51.23M
EBITDA
-$9.52M
Free cash flow
-$40.69M
Per share
Balance sheet
Liquidity
EPS
-$0.33
EPS diluted
-$0.33
Free cash flow per share
-$0.19
Book value per share
-$0.23
Revenue per share
$0.76
TBVPS
$0.77
Total assets
$220.67M
Total liabilities
$269.86M
Debt
$42.24M
Equity
-$49.19M
Working capital
$32.92M
Debt to equity
-0.86
Current ratio
1.41
Quick ratio
1.07
Net debt/EBITDA
1.01
Margins
Efficiency
Dividend
EBITDA margin
-5.9%
Gross margin
60.6%
Net margin
-43.3%
Operating margin
-29.5%
Return on assets
-31.8%
Return on equity
N/A
Return on invested capital
-77.9%
Return on capital employed
-36.7%
Return on sales
-32%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKBA stock price
How has the Akebia Therapeutics stock price performed over time
Intraday
-0.52%
1 week
-2.05%
1 month
3.24%
1 year
17.18%
YTD
0.53%
QTD
-0.52%
Financial performance
How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$160.18M
Gross profit
$97M
Operating income
-$47.25M
Net income
-$69.41M
Gross margin
60.6%
Net margin
-43.3%
AKBA's net margin has dropped by 62% year-on-year and by 60% since the previous quarter
The operating margin has plunged by 58% from the previous quarter and by 33% YoY
AKBA's net income has plunged by 51% from the previous quarter and by 34% YoY
The operating income has declined by 49% since the previous quarter and by 10% year-on-year
Growth
What is Akebia Therapeutics's growth rate over time
Valuation
What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.76
Akebia Therapeutics's EPS has decreased by 43% from the previous quarter and by 18% YoY
The equity has dropped by 61% year-on-year but it is up by 2.4% since the previous quarter
The price to sales (P/S) is 69% more than the 5-year quarterly average of 1.5 and 41% more than the last 4 quarters average of 1.8
Akebia Therapeutics's revenue has decreased by 18% YoY and by 6% QoQ
Efficiency
How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's ROS has plunged by 63% from the previous quarter and by 36% YoY
The ROA has plunged by 54% from the previous quarter and by 54% YoY
The return on invested capital has declined by 40% since the previous quarter and by 6% year-on-year
Dividends
What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKBA.
Financial health
How did Akebia Therapeutics financials performed over time
AKBA's total assets is 18% smaller than its total liabilities
The company's quick ratio rose by 30% YoY and by 6% QoQ
Akebia Therapeutics's current ratio has increased by 19% YoY but it has decreased by 7% QoQ
AKBA's debt is 186% greater than its equity
The equity has dropped by 61% year-on-year but it is up by 2.4% since the previous quarter
The debt to equity has increased by 40% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.